 | |
- close
- close
|
newratings.com
Nov 11
Comment
NEW YORK, November 11 (newratings.com) - Analysts at Needham & Co initiate coverage of Celsion (ticker: CLSN) with a "buy" rating. The target price is set to $7. [more]
Business Wire
Nov 10
Comment
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced financial results for the third quarter ended September 30, 2009 and highlighted the progress made in the commercialization of ThermoDox®, Celsion’s heat
Business Wire
Nov 6
Comment
Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology development company that is leveraging its heat activated liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that
Business Wire
Oct 27
Comment
Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo: 2267) announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of
StreetInsider.com
Oct 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/China%27s+SFDA+Approves+Celsion+Corp.%27s+%28CLSN%29+ThermoDox+for+Phase+III+HEAT+Trial+in+China/5018996.html for the full story.
PR Newswire
Sep 28
Comment
COLUMBIA, Md., Sept. 28 /PRNewswire-FirstCall/ ---- Celsion Corporation (Nasdaq: CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
CLN AT A GLANCE
References
| ||||||
|
|
